Cyberonics' NeuroCybernetic Prosthesis (NCP) system one step nearer to premarket approval (PMA)
This article was originally published in Clinica
Executive Summary
The US FDA has completed its review of Cyberonics' PMA application for the NeuroCybernetic Prosthesis (NCP) System. The PMA for the implantable vagus nerve stimulation device for the treatment of epilepsy patients experiencing refractory partial seizures had been amended in January (see Clinica No 637, p 14).